Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Maggie McConnell's Articles

Arecor appoints Dr. Lindsey Foulkes as Chief Operating Officer

Cambridge, UK: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.

Arecor: Exclusive Formulation Study Collaboration With Par Sterile Products To Develop A Stable Ready To Use Product

Cambridge, UK: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).

Arecor Announces an Exclusive Formulation Study Collaboration with Lilly

Cambridge, UK: Arecor, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study partnership with Eli Lilly and Company.

Arecor granted Key Us Patent

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology platform.

Arecor’s Partner Inhibrx Exercises Its Option To License A New Formulation Developed By Arecor In Accordance With The Terms Of Formulation Development Agreement

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.   This is the first license under a multi-product development agreement between Inhibrx and Arecor.

Arecor Announces Publication Of Phase I Data For AT247 In Diabetes Care

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

Arecor: First Patient Dosed in Phase I Clinical Trial of Ultra-concentrated Rapid Acting Insulin Candidate, at 278, for Diabetes

Arecor Limited , the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278. 

ARECOR to Present at EASD 2020 - Oral Presentation of Phase I Clinical Trial of AT247, A Novel Ultra Rapid Acting Insulin

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting which will be held from 21-25 September 2020.  Abstract #55 is available online.

Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin

Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin.  AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®

Arecor announces the oral presentation of the first Phase I Clinical Trial of AT247, a novel Ultra Rapid Insulin Formulation, at the American Diabetes Association 80th Scientific Sessions

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting which will be held from 12-16 June 2020.  Abstract #231-OR will be available online from 14 June 2020

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.